146 related articles for article (PubMed ID: 38339803)
1. Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma.
De Carlo A; Tosca EM; Fantozzi M; Magni P
Clin Pharmacol Ther; 2024 Apr; 115(4):825-838. PubMed ID: 38339803
[TBL] [Abstract][Full Text] [Related]
2. Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer.
Dosne AG; Valade E; Stuyckens K; De Porre P; Avadhani A; O'Hagan A; Li LY; Ouellet D; Faelens R; Leirens Q; Poggesi I; Perez Ruixo JJ
CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):569-580. PubMed ID: 34755484
[TBL] [Abstract][Full Text] [Related]
3. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
4. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Dosne AG; Valade E; Goeyvaerts N; De Porre P; Avadhani A; O'Hagan A; Li LY; Ouellet D; Perez Ruixo JJ
Cancer Chemother Pharmacol; 2022 Feb; 89(2):151-164. PubMed ID: 34977972
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
[TBL] [Abstract][Full Text] [Related]
6. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
[TBL] [Abstract][Full Text] [Related]
7. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
Loriot Y; O'Hagan A; Siefker-Radtke AO
Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
[TBL] [Abstract][Full Text] [Related]
8. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
9. A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
Tosca EM; Terranova N; Stuyckens K; Dosne AG; Perera T; Vialard J; King P; Verhulst T; Perez-Ruixo JJ; Magni P; Poggesi I
Cancer Chemother Pharmacol; 2022 Jan; 89(1):117-128. PubMed ID: 34786600
[TBL] [Abstract][Full Text] [Related]
10. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Siefker-Radtke AO; Loriot Y
Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
[No Abstract] [Full Text] [Related]
11. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
12. Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
Claiborne RT; Tsan GL
Optom Vis Sci; 2022 Jan; 99(1):88-92. PubMed ID: 34882600
[TBL] [Abstract][Full Text] [Related]
13. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
Franza A; Pirovano M; Giannatempo P; Cosmai L
Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
[TBL] [Abstract][Full Text] [Related]
14. Erdafitinib exerts the anticancer effect on urothelial carcinoma
Jin YY; Tong SQ; Tong M
Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
[TBL] [Abstract][Full Text] [Related]
15. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
[TBL] [Abstract][Full Text] [Related]
17. Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol.
Ribba B; Bräm DS; Baverel PG; Peck RW
CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1497-1510. PubMed ID: 36177959
[TBL] [Abstract][Full Text] [Related]
18. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract][Full Text] [Related]
19. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
20. Biomolecular interactions and binding dynamics of tyrosine kinase inhibitor erdafitinib, with human serum albumin.
Amir M; Qureshi MA; Javed S
J Biomol Struct Dyn; 2021 Jul; 39(11):3934-3947. PubMed ID: 32448054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
